Background: BCAS2 (breast carcinoma amplified sequence 2), also designated DAM1 (DNA amplified in mammary carcinoma 1 protein) or spliceosome-associated SPF 27, is a ubiquitously expressed nuclear protein that was originally identified as being overexpressed in various breast cancer cell lines. BCAS2 is now known to be a component of the spliceosome, participating in the removal of introns from mRNA precursors. BCAS2 specifically interacts (in a ligand-independent manner) with TR∫ (thyroid hormone receptor beta), ERå (estrogen receptor alpha), ER∫, PR (progesterone receptor), and PPAR© (Peroxisome proliferator-activated receptor gamma). BCAS2 functions as an ER coactivator and is capable of enhancing ER-mediated transcription. This suggests that BCAS2 is involved in the development of breast cancer.

Description: Rabbit polyclonal to BCAS2

Immunogen: KLH conjugated synthetic peptide derived from BCAS2

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 26 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.